Strategic collaborations HOOKIPA collaborates with Gilead to develop functional cures for HBV and HIV, indicating openness to co-development and licensing opportunities. Target opportunities with large pharma seeking virology or immunotherapy platforms, especially for chronic infections.

Pipeline expansion Recent asset divestiture and potential portfolio growth through non-binding discussions to acquire Poolbeg Pharma suggest a dynamic M&A and asset-acceleration pathway. Seek partnerships or licensing deals to access complementary assets or fill pipeline gaps.

Arenavirus platform Proprietary arenavirus immunotherapy platform aims to mobilize targeted T cells across HPV16+ cancers, KRAS-mutated tumors, and other programs, signaling opportunities for partnerships on novel immunotherapies and combination strategies with existing oncology franchises.

Clinical-stage focus As a clinical-stage company with revenue in the low range and substantial funding, there is potential for milestone-based partnerships, co-development, and upfront licensing deals to de-risk early-stage programs for larger biopharma.

Operational readiness Small to mid-size team with established tech stack (AWS, SAP SuccessFactors, collaboration tools) suggests readiness for scalable partnerships, data-sharing arrangements, and integrated program management with partner companies.